Albany Molecular Research Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Albany Molecular Research Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012293
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:87
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥34,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥68,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥102,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Albany Molecular Research Inc (AMRI) is a contract research and manufacturing organization. Its service portfolio drug discovery and development, manufacturing of Active Pharmaceutical Ingredients (API); process scale up development of fine chemicals and aseptic filling services for preclinical, clinical and commercial projects; manufacture of drug product (DP) for new and generic drugs and project management services. The company serves pharmaceutical, agrochemical and other sectors including detergent and cosmetics industries. AMRI offers drug discovery and development services across various therapeutic categories including infectious diseases, neurodegenerative disorders, metabolic disorders, cardiovascular and oncology. It has presence in the US, Europe and Asia. AMRI is headquartered in Albany, New York, the US.

Albany Molecular Research Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Albany Molecular Research Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Albany Molecular Research Inc, Medical Devices Deals, 2011 to YTD 2017 11
Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deal Details 15
Private Equity 15
Carlyle Group and GTCR Acquires Albany Molecular Research 15
Mandarin Capital Management Completes Sale Of 30% Stake In Euticals 17
Mandarin Capital Partners And Euticals Acquires 35% Stake In Suzhou Tianma Pharma Group Tianji Bio-Pharma 18
Partnerships 19
Albany Molecular Research Enters into Agreement with Grupo Ferrer and Accord Healthcare 19
Albany Molecular Research Enters into Agreement with University at Albany 20
Nemus Bioscience Enters into Agreement with Albany Molecular Research 21
Albany Molecular Research Enters into Agreement with New York Center for Nanomedicine Research 22
Eagle Pharma Enters into Co-Development Agreement with Albany Molecular Research 23
Albany Molecular Research Enters into Agreement with Icagen 24
Albany Molecular Research Enters into Co-Marketng Agreement with Multispan 25
Albany Molecular Research Enters into Agreement with Saneca Pharma 26
Albany Molecular Research Enters into Agreement with PerkinElmer 27
Albany Molecular Research Enters into Agreement with HarkerBIO 28
Albany Molecular Research Enters Into Smartsourcing Partnership With Codexis 29
Albany Molecular Enters Into An Agreement With Knopp Biosciences For Discovery Services 30
AMRI Enters Into Co-Development Agreement With Biota Holdings For CS8958 31
Creative Antibiotics Enters Into Co-Development Agreement With Albany Molecular Research 32
Proteros biostructures Enters Into An Agreement With Albany Molecular Research 33
Licensing Agreements 34
Denovo Biopharma Enters into Licensing Agreement with Albany Molecular Research 34
Albany Molecular Research Enters into Licensing Agreement with Broad Institute 35
Albany Molecular Research Enters into Licensing Agreement with Teewinot Life Sciences 36
Chai Therapeutics Exercises Option For Licensing Agreement With Albany Molecular Research To Develop ALB 109564(a) 37
AMRI Enters Into Licensing Agreement With Genentech 38
Equity Offering 39
Albany Molecular Research Plans to Raise Funds in Public Offering 39
Albany Molecular Research to Raise Funds through Private Placement of Shares 40
Albany Molecular Research Files Registration Statement For Public Offering Of Securities For US$50 Million 41
Debt Offering 42
Albany Molecular Research Completes Private Placement Of Notes Due 2018 For US$130 Million 42
Acquisition 44
Albany Molecular Research Acquires Euticals 44
Albany Molecular Research Acquires Gadea Grupo Farmaceutico 46
Albany Molecular Research Acquires SSCI from Aptuit for USD36 Million 47
Albany Molecular Research Acquires Aptuit Glasgow from Aptuit for USD24 Million 48
Albany Molecular Research Completes Acquisition of OSO BioPharma for USD110 Million 49
Emami Plans to Acquire 33% Stake in AMRI form Bengal Shrachi Housing Development 50
Albany Molecular Research Acquires Cedarburg Pharmaceuticals 51
Clave Mayor Sells 9.73% Stake In Gadea Grupo Farmaceutico 53
Euticals Acquires Archimica, Fine Chemical Company, From TowerBrook Capital Partners 54
Euticals Acquires 30% Stake in Tianma Tianji Pharma 55
Albany Molecular Research Inc – Key Competitors 56
Albany Molecular Research Inc – Key Employees 57
Albany Molecular Research Inc – Locations And Subsidiaries 58
Head Office 58
Other Locations & Subsidiaries 58
Recent Developments 60
Financial Announcements 60
May 09, 2017: AMRI Announces First Quarter 2017 Results 60
Feb 21, 2017: AMRI Announces Fourth Quarter and Full Year 2016 Results and Provides 2017 Outlook 61
Nov 08, 2016: AMRI ANNOUNCES THIRD QUARTER 2016 RESULTS 64
Aug 04, 2016: AMRI Announces Second Quarter 2016 Results 67
May 10, 2016: AMRI Announces First Quarter 2016 Results 70
Feb 17, 2016: AMRI Announces Fourth Quarter and Full Year 2015 Results and Provides 2016 Outlook 72
Corporate Communications 75
Oct 30, 2017: AMRI Appoints Paul Feuerman as Senior Vice President, General Counsel and Head of Business Development 75
Oct 02, 2017: AMRI Names Joseph D. Sangregorio as Senior Vice President and Chief Human Resources Officer 76
Sep 12, 2017: AMRI Names Stephen Leonard as Senior Vice President Head of Global Operations 77
Feb 17, 2016: AMRI Appoints David H. Deming and Kenneth P. Hagen to Board of Directors 78
Feb 04, 2016: AMRI Appoints Anthony J. Maddaluna to Board of Directors 79
Legal and Regulatory 80
Sep 12, 2017: 3ST Research Files Litigation Alleging Fraud and Conversion of Inventors Intellectual Property Rights by Albany Molecular Research (AMRI) 80
Government and Public Interest 81
Jul 27, 2016: UB CAT awards over $500K to innovative life sciences companies 81
Product News 82
Oct 18, 2017: AMRI’s SSCI Adds Cobalt Light Systems Transmission Raman Spectrometer to Expand Vibrational Spectroscopy Services 82
Other Significant Developments 83
Nov 30, 2017: AMRI Doubles Bulk API Aseptic Manufacturing Capacity 83
Oct 12, 2017: AMRI Launches Stand-Alone Service; Expanding Solutions for Impurity Analysis and Toxicology Risk Assessment 84
Aug 29, 2016: Albany Molecular Research announces restructuring plan of certain operations in U.S.and Europe 85
Jun 14, 2016: AMRI Selected as a Dedicated Chemical Biology Consortium Center to Expand Drug Development 86
Appendix 87
Methodology 87
About GlobalData 87
Contact Us 87
Disclaimer 87

List of Tables
Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Albany Molecular Research Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Albany Molecular Research Inc, Deals By Therapy Area, 2011 to YTD 2017 10
Albany Molecular Research Inc, Medical Devices Deals, 2011 to YTD 2017 11
Albany Molecular Research Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Carlyle Group and GTCR Acquires Albany Molecular Research 15
Mandarin Capital Management Completes Sale Of 30% Stake In Euticals 17
Mandarin Capital Partners And Euticals Acquires 35% Stake In Suzhou Tianma Pharma Group Tianji Bio-Pharma 18
Albany Molecular Research Enters into Agreement with Grupo Ferrer and Accord Healthcare 19
Albany Molecular Research Enters into Agreement with University at Albany 20
Nemus Bioscience Enters into Agreement with Albany Molecular Research 21
Albany Molecular Research Enters into Agreement with New York Center for Nanomedicine Research 22
Eagle Pharma Enters into Co-Development Agreement with Albany Molecular Research 23
Albany Molecular Research Enters into Agreement with Icagen 24
Albany Molecular Research Enters into Co-Marketng Agreement with Multispan 25
Albany Molecular Research Enters into Agreement with Saneca Pharma 26
Albany Molecular Research Enters into Agreement with PerkinElmer 27
Albany Molecular Research Enters into Agreement with HarkerBIO 28
Albany Molecular Research Enters Into Smartsourcing Partnership With Codexis 29
Albany Molecular Enters Into An Agreement With Knopp Biosciences For Discovery Services 30
AMRI Enters Into Co-Development Agreement With Biota Holdings For CS8958 31
Creative Antibiotics Enters Into Co-Development Agreement With Albany Molecular Research 32
Proteros biostructures Enters Into An Agreement With Albany Molecular Research 33
Denovo Biopharma Enters into Licensing Agreement with Albany Molecular Research 34
Albany Molecular Research Enters into Licensing Agreement with Broad Institute 35
Albany Molecular Research Enters into Licensing Agreement with Teewinot Life Sciences 36
Chai Therapeutics Exercises Option For Licensing Agreement With Albany Molecular Research To Develop ALB 109564(a) 37
AMRI Enters Into Licensing Agreement With Genentech 38
Albany Molecular Research Plans to Raise Funds in Public Offering 39
Albany Molecular Research to Raise Funds through Private Placement of Shares 40
Albany Molecular Research Files Registration Statement For Public Offering Of Securities For US$50 Million 41
Albany Molecular Research Completes Private Placement Of Notes Due 2018 For US$130 Million 42
Albany Molecular Research Acquires Euticals 44
Albany Molecular Research Acquires Gadea Grupo Farmaceutico 46
Albany Molecular Research Acquires SSCI from Aptuit for USD36 Million 47
Albany Molecular Research Acquires Aptuit Glasgow from Aptuit for USD24 Million 48
Albany Molecular Research Completes Acquisition of OSO BioPharma for USD110 Million 49
Emami Plans to Acquire 33% Stake in AMRI form Bengal Shrachi Housing Development 50
Albany Molecular Research Acquires Cedarburg Pharmaceuticals 51
Clave Mayor Sells 9.73% Stake In Gadea Grupo Farmaceutico 53
Euticals Acquires Archimica, Fine Chemical Company, From TowerBrook Capital Partners 54
Euticals Acquires 30% Stake in Tianma Tianji Pharma 55
Albany Molecular Research Inc, Key Competitors 56
Albany Molecular Research Inc, Key Employees 57
Albany Molecular Research Inc, Subsidiaries 58

★海外企業調査レポート[Albany Molecular Research Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sime Darby Berhad:企業の戦略・SWOT・財務分析
    Sime Darby Berhad - Strategy, SWOT and Corporate Finance Report Summary Sime Darby Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • DeepOcean Group Holding BV:企業の戦略的SWOT分析
    DeepOcean Group Holding BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • BlueFire Renewables Inc (BFRE):企業の財務・戦略的SWOT分析
    Summary BlueFire Renewables Inc (BlueFire) is a producer and distributor of renewable liquid fuels. The company develops concentrated acid hydrolysis technology process for the profitable conversion of cellulosic waste materials such as green waste to ethanol, and other viable alternatives to petrol …
  • Discount Tire Co:企業の戦略・SWOT・財務分析
    Discount Tire Co - Strategy, SWOT and Corporate Finance Report Summary Discount Tire Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Mitsubishi Electric Corporation:企業のM&A・事業提携・投資動向
    Mitsubishi Electric Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Mitsubishi Electric Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …
  • Formycon AG (FYB):企業の財務・戦略的SWOT分析
    Summary Formycon AG (Formycon) formerly Nanohale AG is a biopharmaceutical company that develops biosimilar drugs candidates. The company offers biopharmaceutical imitation products for global recovery. It provides four biosimilar products in pre-clinical and clinical testing phases. Formycon’s pipe …
  • WEX Pharmaceuticals Inc:企業の戦略的SWOT分析
    WEX Pharmaceuticals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Thomas Cook (India) Limited
    Thomas Cook (India) Limited - Strategy, SWOT and Corporate Finance Report Summary Thomas Cook (India) Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Marubeni Corporation:企業の戦略・SWOT・財務情報
    Marubeni Corporation - Strategy, SWOT and Corporate Finance Report Summary Marubeni Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Eurus Energy America Corp:電力:M&Aディール及び事業提携情報
    Summary Eurus Energy America Corp (Eurus Energy) a subsidiary of Eurus Energy Holdings Corp, is a renewable energy company that develops wind and solar energy projects. The company provides wind project services including land and construction, data collection, operation and maintenance services. It …
  • CardioComm Solutions Inc (EKG):企業の製品パイプライン分析
    Summary CardioComm Solutions Inc (CardioComm) is a medical technology company that offers software solutions for information management systems in cardiovascular medicine and telemedicine. It offers software engineering of computer based electrocardiogram management and reporting software. Its produ …
  • IndigoVision Group plc (IND):企業の財務・戦略的SWOT分析
    Summary IndigoVision Group plc (IndigoVision) is a developer, manufacturer and distributor of end-to-end IP security management systems. The company’s products include management software, cameras and encoders, specialized cameras, body worn video, integration and recorders. Its camera and encoder’s …
  • University of Tennessee Research Foundation:製薬・医療:M&Aディール及び事業提携情報
    Summary University of Tennessee Research Foundation (UTRF) is a non profit organization that promotes commercialization of UT intellectual property and encourages an entrepreneurial culture and contributes to state and regional economic development, and promotes research and education. The organizat …
  • BJ’s Wholesale Club Inc:企業の戦略・SWOT・財務分析
    BJ's Wholesale Club Inc - Strategy, SWOT and Corporate Finance Report Summary BJ's Wholesale Club Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Statewide Superannuation Pty Ltd:企業の戦略的SWOT分析
    Statewide Superannuation Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Grifols SA (GRF):医療機器:M&Aディール及び事業提携情報
    Summary Grifols SA (Grifols) focuses at improving the health and well-being of people around the world. It carries out the research, development, manufacturing and marketing of plasma-derived therapies, hospital pharmacy products and diagnostic technology for clinical use. The company specializes in …
  • Daiichi Sankyo Co Ltd (4568):医療機器:M&Aディール及び事業提携情報
    Summary Daiichi Sankyo Company Ltd (Daiichi Sankyo) is a holding company that carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, over-the-counter (OTC) drugs, vaccines, and others. Its portfolio encompa …
  • DMG America LLC:企業の戦略的SWOT分析
    DMG America LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • GrowMax Resources Corp (BOE):企業の財務・戦略的SWOT分析
    Summary GrowMax Resources Corp (GrowMax), formerly Americas Petrogas Inc is an oil and gas company that offers exploration and development of conventional and unconventional oil and gas properties in Argentina. The company explores and develops phosphate and potassium-rich brine resources in northwe …
  • Air Liquide SA:企業の戦略・SWOT・財務情報
    Air Liquide SA - Strategy, SWOT and Corporate Finance Report Summary Air Liquide SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆